Pharmaceutical law expert Julian Hitchcock spoke to Nature about gene editing regulation and the recent WHO's Committee's recommendations (read Julians initial thoughts here).
The article includes Julian and other experts' comments on the document and addresses registries of clinical studies. Readers will also find the suggestion, previously raised in the 2018 Nuffield Report (of which Julian was a co-author) that leading CRISPR patentees agree to make licences conditional upon ethical use.
Julian's comments were also noticed and mentioned by the German pharmaceutical magazine Pharmazeutische Zeitung, which underlines that while WHO's recommendations are not binding for countries, they still set an important standard that legislators look at.
Science Media Centre also published the reaction of the pharma regulation expert to the recommendations. Julian welcomes "the acknowledgement that governance and regulation must be adaptive to the pace of technological change" and the "recognition that human genome editing is not the only emerging technology of importance".
Bristows invited gene editing experts and professionals to debate the topic at a big event in 2019. Check out our next Life Sciences Summit on the use of AI in the medical field:
Bristows Life Science Summit 2021
Trust in AI in the healthcare sector is one of themes we're going to debate at our next Summit in November '21.
See our events page for further details, and register your interest here.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
